Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 9;21(7):2604.
doi: 10.3390/ijms21072604.

Glyceraldehyde-Derived Pyridinium Evokes Renal Tubular Cell Damage via RAGE Interaction

Affiliations

Glyceraldehyde-Derived Pyridinium Evokes Renal Tubular Cell Damage via RAGE Interaction

Ami Sotokawauchi et al. Int J Mol Sci. .

Abstract

Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) contribute to proximal tubulopathy in diabetes. However, what glycer-AGE structure could evoke tubular cell damage remains unknown. We first examined if deleterious effects of glycer-AGEs on reactive oxygen species (ROS) generation in proximal tubular cells were blocked by DNA-aptamer that could bind to glyceraldehyde-derived pyridinium (GLAP) (GLAP-aptamer), and then investigated whether and how GLAP caused proximal tubular cell injury. GLAP-aptamer and AGE-aptamer raised against glycer-AGEs were prepared using a systemic evolution of ligands by exponential enrichment. The binding affinity of GLAP-aptamer to glycer-AGEs was measured with a bio-layer interferometry. ROS generation was evaluated using fluorescent probes. Gene expression was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). GLAP-aptamer bound to glycer-AGEs with a dissociation constant of 7.7 × 10-5 M. GLAP-aptamer, glycer-AGE-aptamer, or antibodies directed against receptor for glycer-AGEs (RAGE) completely prevented glycer-AGE- or GLAP-induced increase in ROS generation, MCP-1, PAI-1, or RAGE gene expression in tubular cells. Our present results suggest that GLAP is one of the structurally distinct glycer-AGEs, which may mediate oxidative stress and inflammatory reactions in glycer-AGE-exposed tubular cells. Blockade of the interaction of GLAP-RAGE by GLAP-aptamer may be a therapeutic target for proximal tubulopathy in diabetic nephropathy.

Keywords: GLAP; RAGE; diabetic nephropathy; proximal tubular cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
(a) Effects of RAGE-Ab, AGE-aptamer (AGE-apt), or GLAP-aptamer (GLAP-apt), on reactive oxygen species (ROS) generation in glycer-AGE-exposed tubular cells. Tubular cells were treated with 100 μg/mL glycer-AGEs or 100 μg/mL non-glycated bovine serum albumin (BSA) in the presence or absence of 5 μg/mL RAGE-Ab, 10 nM AGE-apt, or 10 nM GLAP-apt for 1 h. ROS generation was evaluated by CellRox oxidative stress reagents. N = 6–12 per group. # and ##, p < 0.05 and p < 0.01 compared to the values with 100 μg/mL glycer-AGEs. (b) The interaction of GLAP-aptamer to immobilized glycer-AGEs was analyzed by bio-layer interferometry. N = 4 per group.
Figure 2
Figure 2
Effects of glyceraldehyde-derived pyridinium (GLAP) or GLAP-aptamer (GLAP-apt) on ROS generation (a,b), MCP-1 (c), PAI-1 (d), and RAGE mRNA levels (e) in proximal tubular cells. Tubular cells were treated with the indicated concentrations of GLAP in the presence or absence of 5 μg/mL RAGE-Ab, 10 nM AGE-apatmer (AGE-apt), or 10nM GLAP-apt for 1 h (a,b) or for 4 h (ce). ROS generation was evaluated by CellRox oxidative stress reagents. N = 6 per group (ce). Total RNAs were transcribed and amplified by real-time PCR. Data were normalized by the intensity of 18S rRNA mRNA-derived signals and then related to the control values. (c,d) N = 3 per group. (e) N = 7 per group. **, p < 0.01 compared to the control values. # and ##, p < 0.05 and p < 0.01 compared to the values with 10 μg/mL GLAP alone, respectively.

References

    1. IDF Diabetes Atlas-9th Edition. [(accessed on 6 April 2020)]; Available online: https://www.diabetesatlas.org/en/
    1. Yamagishi S.I., Nakamura N., Matsui T. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory. J. Diabetes. 2017;9:141–148. doi: 10.1111/1753-0407.12475. - DOI - PubMed
    1. Yamagishi S., Nakamura N., Suematsu M., Kaseda K., Matsui T. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Mol. Med. 2015;21:S32–S40. doi: 10.2119/molmed.2015.00067. - DOI - PMC - PubMed
    1. Tahara N., Yamagishi S., Matsui T., Takeuchi M., Nitta Y., Kodama N., Mizoguchi M., Imaizumi T. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc. Ther. 2012;30:42–48. doi: 10.1111/j.1755-5922.2010.00177.x. - DOI - PubMed
    1. Kaida Y., Fukami K., Matsui T., Higashimoto Y., Nishino Y., Obara N., Nakayama Y., Ando R., Toyonaga M., Ueda S., et al. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes. 2013;62:3241–3250. doi: 10.2337/db12-1608. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources